---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-021414"
form_type: "8-K"
ticker: "RYTM"
cik: "0001649904"
company_name: "RHYTHM PHARMACEUTICALS, INC."
filed_at: "2026-03-26T23:59:59+00:00"
generated_at: "2026-05-15T08:50:34.492053+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Rhythm Pharma gets positive CHMP opinion to expand IMCIVREE label for acquired hypothalamic obesity

## Summary
- CHMP recommends expanding IMCIVREE (setmelanotide) marketing authorization to treat obesity/control hunger in patients >=4 years with acquired HO due to hypothalamic injury.
- European Commission decision on label expansion anticipated in Q2 2026.
- Follows FDA approval last week; CEO cites broad label and global drug development approach.
- Acquired HO is a rare neuroendocrine disease with impaired MC4R pathway signaling causing rapid weight gain and hyperphagia.

## SEC filing metadata
- accession: 0001628280-26-021414
- form_type: 8-K
- ticker: RYTM
- cik: 0001649904
- company_name: RHYTHM PHARMACEUTICALS, INC.
- filed_at: 2026-03-26T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649904/000162828026021414/0001628280-26-021414-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649904/000162828026021414/rytm-20260326.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-021414
- JSON: https://secwatch.observer/filing/0001628280-26-021414.json
- Plain text: https://secwatch.observer/filing/0001628280-26-021414.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.